We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now


It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Registration Strip Icon for alerts Register for real-time alerts, custom portfolio, and market movers

BIVI BioVie Inc

-0.11 (-6.11%)
Dec 02 2023 - Closed
Delayed by 15 minutes


Draw Mode:

Volume 1,314,619
Bid Price 1.69
Ask Price 50.00
News -
Day High 1.79


52 Week Range


Day Low 1.6301
Company Name Stock Ticker Symbol Market Type
BioVie Inc BIVI NASDAQ Common Stock
  Price Change Change Percent Stock Price Last Traded
-0.11 -6.11% 1.69 00:00:09
Open Price Low Price High Price Close Price Prev Close
1.74 1.6301 1.79 1.68 1.80
Trades Volume VWAP Dollar Volume Avg Volume 52 Week Range
5,951 1,314,619 $ 1.70 $ 2,234,182 - 1.50 - 14.38
Last Trade Time Type Quantity Stock Price Currency
19:56:45 50 $ 1.75 USD

BioVie Inc Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
64.54M 37.74M - 0 -50.26M -1.33 -
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- - - -

more financials information »

BioVie News

Loading Messages....

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....

No posts yet, be the first! No BIVI Message Board. Create One! See More Posts on BIVI Message Board See More Message Board Posts

Historical BIVI Price Data

Period Open High Low VWAP Avg. Daily Vol Change %
1 Week4.995.6541.502.412,700,390-3.30-66.13%
1 Month4.455.821.503.081,245,181-2.76-62.02%
3 Months3.275.821.503.29685,554-1.58-48.32%
6 Months5.946.451.503.67440,345-4.25-71.55%
1 Year6.7514.381.506.25591,735-5.06-74.96%
3 Years9.8046.09771.3256.76279,937-8.11-82.76%
5 Years10.5046.09771.3256.78264,507-8.81-83.9%

BioVie Description

BioVie Inc is a company developing innovative drug therapies to treat chronic debilitating conditions including liver disease and neurological and neuro-degenerative disorders and certain cancers. The company is currently focused on developing and commercializing BIV201, a novel investigational approach to the treatment of ascites due to chronic liver cirrhosis. BIV201 has the potential to improve the health of thousands of patients suffering from life-threatening complications of liver cirrhosis due to hepatitis, non-alcoholic steatohepatitis and alcoholism.

Your Recent History

Delayed Upgrade Clock

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

Support: 1-888-992-3836 |